Eli Lilly & Company (NYSE:lily) is one of them. 13 highly profitable stocks to invest in now.
Pixabay/Public Domain
February 2, 2026 Reuters Long-held expectations that the global obesity drug market would reach $150 billion over the next 10 years are being revised amid falling prices and increased competition for GLP-1 drugs in the United States. New forecasts show the market will reach nearly $100 billion by 2030, about 30% less than previous predictions. Furthermore, it is expected that it will not reach the $150 billion level until 2035.
Jefferies slashed its peak market forecast by 20% in January, citing pressure from cash competition and stronger-than-expected generic drug entry. The company’s market size in 2035 is expected to be $80 billion.
Even with these revised assumptions, LSEG’s consensus estimates still project Eli Lilly & Company (NYSE:LLY) to deliver revenue growth of more than 21% and adjusted earnings growth of more than 40% in 2026 compared to 2025.
Against this backdrop of demand, Lilly outlined its strategic initiatives two days ago.
January 30, 2026 Eli Lilly & Company (NYSE: LLY) announced the construction of a $3.5 billion pharmaceutical manufacturing facility in Pennsylvania, its fourth new location in the United States. As GLP-1 competition accelerates, the plant will produce injectable weight loss drugs like letaltortide, and construction is expected to begin this year and begin operations in 2031.
Eli Lilly & Company (NYSE:LLY) develops and commercializes innovative medicines across diabetes, obesity, oncology, immunology and neuroscience.
While we recognize LLY’s potential as an investment, we believe certain AI stocks offer more upside potential and less downside risk. If you’re looking for highly undervalued AI stocks that could also benefit greatly from Trump-era tariffs and onshoring trends, check out our free report on the best AI stocks in the short term.
Read next: What are the best stocks to buy now? and 10 stocks soaring below $1.
Disclosure: none.